10 Hudson Yards
37th Floor
New York, NY 10001
United States
646 747 1000
https://www.interceptpharma.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 437
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Jerome B. Durso | Pres, CEO & Director | 1,16M | N/A | 1968 |
Mr. Andrew Saik | Chief Financial Officer | 485,07k | N/A | 1969 |
Mr. Rocco Venezia | Chief Accounting Officer & Treasurer | 660,62k | N/A | 1976 |
Mr. Jared M. Freedberg J.D. | Gen. Counsel | 691,46k | N/A | 1968 |
Dr. M. Michelle Berrey M.D., M.P.H., MPH. | Pres of R&D and Chief Medical Officer | 732,13k | N/A | 1967 |
Mr. Bryan Ball | Chief Quality Officer & Sr. VP of Operations | N/A | N/A | 1970 |
Mr. David Ford | Chief HR Officer | N/A | N/A | 1970 |
Dr. Mark Pruzanski M.D. | Founder, Advisor & Director | N/A | N/A | 1968 |
Ms. Linda M. Richardson | Exec. VP & Chief Commercial Officer | N/A | N/A | 1964 |
Paul Nitschmann | Sr. VP of Regulatory Affairs | N/A | N/A | N/A |
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
El ISS Governance QualityScore de Intercept Pharmaceuticals, Inc., a día 31 de julio de 2022, es 6. Las puntuaciones base son Auditoría: 8; Tablero: 3; Derechos de los accionistas: 7; Compensación: 9.